Bafna Pharmaceuticals Ltd banner

Bafna Pharmaceuticals Ltd
NSE:BAFNAPH

Watchlist Manager
Bafna Pharmaceuticals Ltd Logo
Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
Watchlist
Price: 136.02 INR -0.73%
Market Cap: ₹3.2B

Bafna Pharmaceuticals Ltd
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Bafna Pharmaceuticals Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
Free Cash Flow
-₹135.5m
CAGR 3-Years
-1%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Free Cash Flow
₹18.5B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Free Cash Flow
₹27B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Free Cash Flow
₹89B
CAGR 3-Years
53%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Lupin Ltd
NSE:LUPIN
Free Cash Flow
₹29.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Free Cash Flow
₹13.6B
CAGR 3-Years
-4%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

Bafna Pharmaceuticals Ltd
Glance View

Market Cap
3.2B INR
Industry
Pharmaceuticals

Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is manufacturing over 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. The firm caters to both domestic and international markets. The firm has two manufacturing facilities in Chennai. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The firm supplies its finished products to countries including Sri Lanka, Ghana, Ukraine, and Laos. The firm's subsidary include Bafna Lifestyles Remedies Limited.

BAFNAPH Intrinsic Value
80.69 INR
Overvaluation 41%
Intrinsic Value
Price ₹136.02

See Also

What is Bafna Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
-135.5m INR

Based on the financial report for Dec 31, 2025, Bafna Pharmaceuticals Ltd's Free Cash Flow amounts to -135.5m INR.

What is Bafna Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
20%

Over the last year, the Free Cash Flow growth was -94%. The average annual Free Cash Flow growth rates for Bafna Pharmaceuticals Ltd have been -1% over the past three years , 20% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett